Autoantibody Against Ferritin Light Chain is a Serum Biomarker for the Detection of Liver Cirrhosis but Not Liver Cancer

References

• Sung H, Ferlay J, Siegel RL. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Colli A, Nadarevic T, Miletic D, et al. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev. 2021;4(4):Cd013346. doi:10.1002/14651858.CD013346.pub2
   PubMed Web of Science ®Google Scholar
• Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72(2):250–261. doi:10.1016/j.jhep.2019.08.025
   PubMed Web of Science ®Google Scholar
• Demirtas CO, Brunetto MR. Surveillance for hepatocellular carcinoma in chronic viral hepatitis: is it time to personalize it? World J Gastroenterol. 2021;27(33):5536–5554. doi:10.3748/wjg.v27.i33.5536
   PubMed Web of Science ®Google Scholar
• Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: an evidence-based approach. World J Gastroenterol. 2019;25(13):1550–1559. doi:10.3748/wjg.v25.i13.1550
   PubMed Web of Science ®Google Scholar
• Zhang G, Ha SA, Kim HK, et al. Combined analysis of AFP and HCCR-1 as an useful serological marker for small hepatocellular carcinoma: a prospective cohort study. Dis Markers. 2012;32(4):265–271. doi:10.1155/2012/964036
   PubMed Web of Science ®Google Scholar
• Saffroy R, Pham P, Reffas M, Takka M, Lemoine A, Debuire B. New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med. 2007;45(9):1169–1179. doi:10.1515/CCLM.2007.262
   PubMed Web of Science ®Google Scholar
• Hanif H, Ali MJ, Susheela AT, et al. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol. 2022;28(2):216–229. doi:10.3748/wjg.v28.i2.216
   PubMed Web of Science ®Google Scholar
• Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(6):1706–1718.e1701. doi:10.1053/j.gastro.2018.01.064
   PubMed Web of Science ®Google Scholar
• Wang T, Zhang KH. New blood biomarkers for the diagnosis of AFP-negative hepatocellular carcinoma. Front Oncol. 2020;10:1316. doi:10.3389/fonc.2020.01316
   PubMed Web of Science ®Google Scholar
• Chen F, Wang J, Wu Y, Gao Q, Zhang S. Potential biomarkers for liver cancer diagnosis based on multi-omics strategy. Front Oncol. 2022;12:822449. doi:10.3389/fonc.2022.822449
   PubMed Web of Science ®Google Scholar
• Li C, Zhang Z, Zhang P, Liu J. Diagnostic accuracy of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatocellular carcinoma: a systematic review. Hepatol Res. 2014;44(10):E11–E25. doi:10.1111/hepr.12201
   PubMed Web of Science ®Google Scholar
• Xing H, Zheng YJ, Han J, et al. Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: a systematic review with meta-analysis. Hepatobiliary Pancreat Dis Int. 2018;17(6):487–495. doi:10.1016/j.hbpd.2018.09.009
   PubMed Web of Science ®Google Scholar
• Feng H, Li B, Li Z, Wei Q, Ren L. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer. 2021;21(1):401. doi:10.1186/s12885-021-08138-3
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang W, Liu Y, et al. Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma. Infect Agent Cancer. 2017;12:47. doi:10.1186/s13027-017-0153-6
   PubMed Web of Science ®Google Scholar
• Zhang JY, Tan EM. Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. Expert Rev Mol Diagn. 2010;10(3):321–328. doi:10.1586/erm.10.12
   PubMed Web of Science ®Google Scholar
• Alkhateeb AA, Connor JR. The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. Biochim Biophys Acta. 2013;1836(2):245–254. doi:10.1016/j.bbcan.2013.07.002
   PubMed Web of Science ®Google Scholar
• Hu ZW, Chen L, Ma RQ, et al. Comprehensive analysis of ferritin subunits expression and positive correlations with tumor-associated macrophages and T regulatory cells infiltration in most solid tumors. Aging. 2021;13(8):11491–11506. doi:10.18632/aging.202841
   PubMedGoogle Scholar
• Ciregia F, Giusti L, Molinaro A, et al. Presence in the pre-surgical fine-needle aspiration of potential thyroid biomarkers previously identified in the post-surgical one. PLoS One. 2013;8(9):e72911. doi:10.1371/journal.pone.0072911
   PubMed Web of Science ®Google Scholar
• An HJ, Kim DS, Park YK, et al. Comparative proteomics of ovarian epithelial tumors. J Proteome Res. 2006;5(5):1082–1090. doi:10.1021/pr050461p
   PubMed Web of Science ®Google Scholar
• Lin CY, Lin CJ, Chen KH, Wu JC, Huang SH, Wang SM. Macrophage activation increases the invasive properties of hepatoma cells by destabilization of the adherens junction. FEBS Lett. 2006;580(13):3042–3050. doi:10.1016/j.febslet.2006.04.049
   PubMed Web of Science ®Google Scholar
• Weinstein RE, Bond BH, Silberberg BK. Tissue ferritin concentration in carcinoma of the breast. Cancer. 1982;50(11):2406–2409. doi:10.1002/1097-0142(19821201)50:11<2406::AID-CNCR2820501127>3.0.CO;2-S
   PubMed Web of Science ®Google Scholar
• Wu T, Li Y, Liu B, et al. Expression of ferritin light chain (FTL) is elevated in glioblastoma, and FTL silencing inhibits glioblastoma cell proliferation via the GADD45/JNK pathway. PLoS One. 2016;11(2):e0149361. doi:10.1371/journal.pone.0149361
   PubMed Web of Science ®Google Scholar
• Li Z, Liu J, Chen H, et al. Ferritin Light Chain (FTL) competes with long noncoding RNA Linc00467 for miR-133b binding site to regulate chemoresistance and metastasis of colorectal cancer. Carcinogenesis. 2020;41(4):467–477. doi:10.1093/carcin/bgz181
   PubMed Web of Science ®Google Scholar
• Zhang L, Chen Z, Xu A. FTL: a novel predictor in gastric cancer. Int J Clin Exp Pathol. 2017;10(7):7865–7872.
   PubMed Web of Science ®Google Scholar
• Wang K, Xu X, Nie Y, Dai L, Wang P, Zhang J. Identification of tumor-associated antigens by using SEREX in hepatocellular carcinoma. Cancer Lett. 2009;281(2):144–150. doi:10.1016/j.canlet.2009.02.037
   PubMed Web of Science ®Google Scholar
• Wang K, Li M, Qin J, et al. Serological biomarkers for early detection of hepatocellular carcinoma: a focus on autoantibodies against tumor-associated antigens encoded by cancer driver genes. Cancers. 2020;12(5):1271. doi:10.3390/cancers12051271
   PubMed Web of Science ®Google Scholar
• Zhang HF, Qin JJ, Ren PF, et al. A panel of autoantibodies against multiple tumor-associated antigens in the immunodiagnosis of esophageal squamous cell cancer. Cancer Immunol Immunother. 2016;65(10):1233–1242. doi:10.1007/s00262-016-1886-6
   PubMed Web of Science ®Google Scholar
• Lavoie DJ, Marcus DM, Otsuka S, Listowsky I. Characterization of ferritin from human placenta. Implications for analysis of tissue specificity and microheterogeneity of ferritins. Biochim Biophys Acta. 1979;579(2):359–366. doi:10.1016/0005-2795(79)90063-1
   PubMed Web of Science ®Google Scholar
• Ahmad S, Moriconi F, Naz N, et al. Ferritin L and Ferritin H are differentially located within hepatic and extra hepatic organs under physiological and acute phase conditions. Int J Clin Exp Pathol. 2013;6(4):622–629.
   PubMed Web of Science ®Google Scholar
• Plays M, Muller S, Rodriguez R. Chemistry and biology of ferritin. Metallomics. 2021;13(5). doi:10.1093/mtomcs/mfab021
   PubMed Web of Science ®Google Scholar
• Asperti M, Bellini S, Grillo E, et al. H-ferritin suppression and pronounced mitochondrial respiration make Hepatocellular Carcinoma cells sensitive to RSL3-induced ferroptosis. Free Radic Biol Med. 2021;169:294–303. doi:10.1016/j.freeradbiomed.2021.04.024
   PubMed Web of Science ®Google Scholar
• Shpyleva SI, Tryndyak VP, Kovalchuk O, et al. Role of ferritin alterations in human breast cancer cells. Breast Cancer Res Treat. 2011;126(1):63–71. doi:10.1007/s10549-010-0849-4
   PubMed Web of Science ®Google Scholar
• Feng Z, Chen JW, Feng JH, et al. The association between serum ferritin with colorectal cancer. Int J Clin Exp Med. 2015;8(12):22293–22299.
   PubMed Web of Science ®Google Scholar
• Wu SJ, Zhang ZZ, Cheng NS, Xiong XZ, Yang L. Preoperative serum ferritin is an independent prognostic factor for liver cancer after hepatectomy. Surg Oncol. 2019;29:159–167. doi:10.1016/j.suronc.2019.05.013
   PubMed Web of Science ®Google Scholar
• Lee S, Jeon H, Shim B. Prognostic value of ferritin-to-hemoglobin ratio in patients with advanced non-small-cell lung cancer. J Cancer. 2019;10(7):1717–1725. doi:10.7150/jca.26853
   PubMed Web of Science ®Google Scholar
• Ramirez-Carmona W, Diaz-Fabregat B, Yuri Yoshigae A, et al. Are serum ferritin levels a reliable cancer biomarker? A systematic review and meta-analysis. Nutr Cancer. 2021:1–10. doi:10.1080/01635581.2021.1982996
   Web of Science ®Google Scholar
• Shen Y, Li X, Zhao B, et al. Iron metabolism gene expression and prognostic features of hepatocellular carcinoma. J Cell Biochem. 2018;119(11):9178–9204. doi:10.1002/jcb.27184
   PubMed Web of Science ®Google Scholar
• Meynard D, Babitt JL, Lin HY. The liver: conductor of systemic iron balance. Blood. 2014;123(2):168–176. doi:10.1182/blood-2013-06-427757
   PubMed Web of Science ®Google Scholar
• Wei Y, Ye W, Zhao W. Serum iron levels decreased in patients with HBV-related hepatocellular carcinoma, as a risk factor for the prognosis of HBV-related HCC. Front Physiol. 2018;9:66. doi:10.3389/fphys.2018.00066
   PubMed Web of Science ®Google Scholar
• Haghgoo SM, Sharafi H, Alavian SM. Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: a systematic review. Clin Chem Lab Med. 2019;57(5):577–610. doi:10.1515/cclm-2018-0357
   PubMed Web of Science ®Google Scholar
• Angulo P, George J, Day CP, et al. Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12(7):1163–1169 e1161. doi:10.1016/j.cgh.2013.11.035
   PubMed Web of Science ®Google Scholar
• Yoneda M, Thomas E, Sumida Y, et al. Clinical usage of serum ferritin to assess liver fibrosis in patients with non-alcoholic fatty liver disease: proceed with caution. Hepatol Res. 2014;44(14):E499–E502. doi:10.1111/hepr.12327
   PubMed Web of Science ®Google Scholar
• Mao W, Hu Y, Lou Y, Chen Y, Zhang J. Abnormal serum iron markers in chronic hepatitis B virus infection may be because of liver injury. Eur J Gastroenterol Hepatol. 2015;27(2):130–136. doi:10.1097/MEG.0000000000000247
   PubMed Web of Science ®Google Scholar
• Yu K, Li Q, Shi G, Li N. Involvement of epithelial-mesenchymal transition in liver fibrosis. Saudi J Gastroenterol. 2018;24(1):5–11. doi:10.4103/sjg.SJG_297_17
   PubMed Web of Science ®Google Scholar
• Chen Y, Fan Y, Guo DY, et al. Study on the relationship between hepatic fibrosis and epithelial-mesenchymal transition in intrahepatic cells. Biomed Pharmacother. 2020;129:110413. doi:10.1016/j.biopha.2020.110413
   PubMed Web of Science ®Google Scholar
• Jezequel P, Campion L, Spyratos F, et al. Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: a multicentric 2004 national PHRC study. Int J Cancer. 2012;131(2):426–437. doi:10.1002/ijc.26397
   PubMed Web of Science ®Google Scholar
• Liu J, Gao L, Zhan N, et al. Hypoxia induced ferritin light chain (FTL) promoted epithelia mesenchymal transition and chemoresistance of glioma. J Exp Clin Cancer Res. 2020;39(1):137. doi:10.1186/s13046-020-01641-8
   PubMed Web of Science ®Google Scholar